Phase I study of combination drug purging for autologous bone marrow transplantation

Scott D. Rowley, Carole B. Miller, Steven Piantadosi, Janice Davis Sproul, George W. Santos, Richard J Jones

Research output: Contribution to journalArticle

Abstract

In a phase I clinical trial of autologous bone marrow transplantation, we determined the feasibility of ex vivo purging with high concentrations of pharmacologics in combination. Light-density cells isolated from the grafts of 26 patients with acute leukemia or lymphoblastic lymphoma were treated with 4-hydroperoxycyclophosphamide (4-HC; 30 to 60 μg/mL), vincristine (Vcr; 1.5 to 3.0 μg/mL), and methylprednisolone sodium succinate (MP; 5 mg/mL). All patients received marrow-lethal induction therapy followed by infusion of the treated grafts. Three patients died of transplantrelated complications before achieving peripheral blood recovery of greater than 0.5 × 109 granulocytes per liter. All other patients achieved this parameter of engraftment at a median of 35 days after marrow infusion. The median time to last platelet transfusion was 45 days. These durations of aplasia were similar to those experienced by other patients receiving density-gradient separated grafts treated with 60 ×g/mL of 4-HC as a single agent. No patient required infusion of untreated reserve marrow because of engraftment failure. The colony-forming unit-granulocyte macrophage (CFU-GM) content of the grafts after purging predicted these parameters of engraftment. Colony-forming unit - leukemia (CFU-L) cultured from the grafts of 12 of the patients treated for acute lymphoblastic leukemia (ALL) were considerably more sensitive to the combination regimen than to 4-HC alone; the sensitivity of CFU-GM from these patients did not differ between the two regimens. The results of this trial indicate the feasibility of treating autologous bone marrow grafts with high concentrations of pharmacologies in combination. The use of combinations may increase the efficacy of ex vivo purging without increasing the toxicity to normal hematopoietic cells.

Original languageEnglish (US)
Pages (from-to)2210-2218
Number of pages9
JournalJournal of Clinical Oncology
Volume9
Issue number12
StatePublished - Dec 1991

Fingerprint

Autologous Transplantation
Drug Combinations
Bone Marrow Transplantation
Transplants
Bone Marrow
Granulocyte-Macrophage Progenitor Cells
perfosfamide
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
Methylprednisolone Hemisuccinate
Platelet Transfusion
Clinical Trials, Phase I
Vincristine
Granulocytes
Stem Cells
Cell Count
Pharmacology
Light

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase I study of combination drug purging for autologous bone marrow transplantation. / Rowley, Scott D.; Miller, Carole B.; Piantadosi, Steven; Davis Sproul, Janice; Santos, George W.; Jones, Richard J.

In: Journal of Clinical Oncology, Vol. 9, No. 12, 12.1991, p. 2210-2218.

Research output: Contribution to journalArticle

Rowley, Scott D. ; Miller, Carole B. ; Piantadosi, Steven ; Davis Sproul, Janice ; Santos, George W. ; Jones, Richard J. / Phase I study of combination drug purging for autologous bone marrow transplantation. In: Journal of Clinical Oncology. 1991 ; Vol. 9, No. 12. pp. 2210-2218.
@article{512986d307a444c1be64cb4c765b87aa,
title = "Phase I study of combination drug purging for autologous bone marrow transplantation",
abstract = "In a phase I clinical trial of autologous bone marrow transplantation, we determined the feasibility of ex vivo purging with high concentrations of pharmacologics in combination. Light-density cells isolated from the grafts of 26 patients with acute leukemia or lymphoblastic lymphoma were treated with 4-hydroperoxycyclophosphamide (4-HC; 30 to 60 μg/mL), vincristine (Vcr; 1.5 to 3.0 μg/mL), and methylprednisolone sodium succinate (MP; 5 mg/mL). All patients received marrow-lethal induction therapy followed by infusion of the treated grafts. Three patients died of transplantrelated complications before achieving peripheral blood recovery of greater than 0.5 × 109 granulocytes per liter. All other patients achieved this parameter of engraftment at a median of 35 days after marrow infusion. The median time to last platelet transfusion was 45 days. These durations of aplasia were similar to those experienced by other patients receiving density-gradient separated grafts treated with 60 ×g/mL of 4-HC as a single agent. No patient required infusion of untreated reserve marrow because of engraftment failure. The colony-forming unit-granulocyte macrophage (CFU-GM) content of the grafts after purging predicted these parameters of engraftment. Colony-forming unit - leukemia (CFU-L) cultured from the grafts of 12 of the patients treated for acute lymphoblastic leukemia (ALL) were considerably more sensitive to the combination regimen than to 4-HC alone; the sensitivity of CFU-GM from these patients did not differ between the two regimens. The results of this trial indicate the feasibility of treating autologous bone marrow grafts with high concentrations of pharmacologies in combination. The use of combinations may increase the efficacy of ex vivo purging without increasing the toxicity to normal hematopoietic cells.",
author = "Rowley, {Scott D.} and Miller, {Carole B.} and Steven Piantadosi and {Davis Sproul}, Janice and Santos, {George W.} and Jones, {Richard J}",
year = "1991",
month = "12",
language = "English (US)",
volume = "9",
pages = "2210--2218",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Phase I study of combination drug purging for autologous bone marrow transplantation

AU - Rowley, Scott D.

AU - Miller, Carole B.

AU - Piantadosi, Steven

AU - Davis Sproul, Janice

AU - Santos, George W.

AU - Jones, Richard J

PY - 1991/12

Y1 - 1991/12

N2 - In a phase I clinical trial of autologous bone marrow transplantation, we determined the feasibility of ex vivo purging with high concentrations of pharmacologics in combination. Light-density cells isolated from the grafts of 26 patients with acute leukemia or lymphoblastic lymphoma were treated with 4-hydroperoxycyclophosphamide (4-HC; 30 to 60 μg/mL), vincristine (Vcr; 1.5 to 3.0 μg/mL), and methylprednisolone sodium succinate (MP; 5 mg/mL). All patients received marrow-lethal induction therapy followed by infusion of the treated grafts. Three patients died of transplantrelated complications before achieving peripheral blood recovery of greater than 0.5 × 109 granulocytes per liter. All other patients achieved this parameter of engraftment at a median of 35 days after marrow infusion. The median time to last platelet transfusion was 45 days. These durations of aplasia were similar to those experienced by other patients receiving density-gradient separated grafts treated with 60 ×g/mL of 4-HC as a single agent. No patient required infusion of untreated reserve marrow because of engraftment failure. The colony-forming unit-granulocyte macrophage (CFU-GM) content of the grafts after purging predicted these parameters of engraftment. Colony-forming unit - leukemia (CFU-L) cultured from the grafts of 12 of the patients treated for acute lymphoblastic leukemia (ALL) were considerably more sensitive to the combination regimen than to 4-HC alone; the sensitivity of CFU-GM from these patients did not differ between the two regimens. The results of this trial indicate the feasibility of treating autologous bone marrow grafts with high concentrations of pharmacologies in combination. The use of combinations may increase the efficacy of ex vivo purging without increasing the toxicity to normal hematopoietic cells.

AB - In a phase I clinical trial of autologous bone marrow transplantation, we determined the feasibility of ex vivo purging with high concentrations of pharmacologics in combination. Light-density cells isolated from the grafts of 26 patients with acute leukemia or lymphoblastic lymphoma were treated with 4-hydroperoxycyclophosphamide (4-HC; 30 to 60 μg/mL), vincristine (Vcr; 1.5 to 3.0 μg/mL), and methylprednisolone sodium succinate (MP; 5 mg/mL). All patients received marrow-lethal induction therapy followed by infusion of the treated grafts. Three patients died of transplantrelated complications before achieving peripheral blood recovery of greater than 0.5 × 109 granulocytes per liter. All other patients achieved this parameter of engraftment at a median of 35 days after marrow infusion. The median time to last platelet transfusion was 45 days. These durations of aplasia were similar to those experienced by other patients receiving density-gradient separated grafts treated with 60 ×g/mL of 4-HC as a single agent. No patient required infusion of untreated reserve marrow because of engraftment failure. The colony-forming unit-granulocyte macrophage (CFU-GM) content of the grafts after purging predicted these parameters of engraftment. Colony-forming unit - leukemia (CFU-L) cultured from the grafts of 12 of the patients treated for acute lymphoblastic leukemia (ALL) were considerably more sensitive to the combination regimen than to 4-HC alone; the sensitivity of CFU-GM from these patients did not differ between the two regimens. The results of this trial indicate the feasibility of treating autologous bone marrow grafts with high concentrations of pharmacologies in combination. The use of combinations may increase the efficacy of ex vivo purging without increasing the toxicity to normal hematopoietic cells.

UR - http://www.scopus.com/inward/record.url?scp=0025876171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025876171&partnerID=8YFLogxK

M3 - Article

C2 - 1960561

AN - SCOPUS:0025876171

VL - 9

SP - 2210

EP - 2218

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -